Neurocrine's movement disorder drug meets main goal in mid-stage study
(Reuters) - Neurocrine Biosciences Inc said its movement disorder drug showed a reduction in symptoms compared to a placebo in a mid-stage study, send...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/yIMzlh6vwQo/story01.htm
No comments:
Post a Comment